Connect Global Healthcare Innovations with World Class Opportunities in the Chinese Market
COMPANY OVERVIEW
Founded in 2018, Intercontinental Capital is a premier cross-border financial advisory firm that is solely focused on the healthcare sector, including medical devices, pharmaceuticals, digital health and healthcare services.
With offices in Shanghai, Hong Kong, London and Zurich, Intercontinental Capital has developed unparalleled industry knowledge, expertise and resources in each local market, and established high level cooperation with hundreds of top investment funds, hospitals, KOLS and healthcare companies globally.
By leveraging strong global resources and vast networks in the US, Europe and China, we are able to connect global healthcare innovations with world class opportunities in the Chinese Market. We bring a wealth of experience to provide global innovators with financial, marketing and regulatory resources to enter the Chinese market and find the right local partners to unlock the China’s huge market potential. We assist Chinese companies and investor to gain deep insights of global healthcare trends, gain access to global markets, and connect with global innovative projects and companies.
WHO WE WORK WITH
We Work with China’s Top Healthcare VC Funds:
We Work with China’s Top Healthcare Companies:
Our Partners in Europe
We Work with China’s Top Healthcare Companies:
We Work with China’s Top Healthcare Companies:
Kinled is a company which retains the assets of the Anglo-Austrian Aisher Family through direct investments in innovative businesses in the Life Science and Digital Technology sectors.
With roots going back to 1924, Kinled was founded to retain investment assets for the Aisher Family. Since 1990, the investment focus shifted to early stage ventures.
Today, in life sciences, we have a laser-focus on innovation in the biomedical technology, medical devices, bio pharmaceuticals, and healthcare services sectors, which represents over 50% of our portfolio.
In digital technologies, we invest in SaaS-enabled networks and marketplaces, where technology can democratize markets and provide consumers with greater choice of services.
In fintech, we invest in companies that use technology to challenge the traditional established institutions by providing superior service in embedded payment platforms, insurance, real estate, lending and banking.
Kinled Holding is a Partner in four dedicated life science investment companies based in Boston, Vienna, Gibraltar and Zurich, with combined Assets under Management of $250M, and two specific digital technology Funds based in Vienna and London with combined Assets under Management of €225M.
40
Direct Investments
130
Current Portfolio
4x +
Investment Multiple
32
Exits
8
Indirect Investments
Mountain Labs is Switzerland’s first full service search lab: an early-stage incubator, direct investor and corporate finance vehicle, supporting entrepreneurs and investors from day one through to exits.
Who we are?
Our founding partners are a group of like-minded family offices and investment professionals from around the globe who have all historically invested in Swiss enterprises and have developed deep connections within the region.
Our Solution:
-
Mountain Labs provides a haven for founders to build their products and removes so much of the noise and distractions that can usually hamper early-stage companies.
-
With the support of great teams and in a unique creative environment our Startups and Founders will be able to build, test, brand and ship innovative products in a short period of time.
ALLOWING FAMILY OFFICES AND HNWIS ACCESS TO WORLD-CLASS INVESTMENT OPPORTUNITIES AND A NETWORK OF LIKE-MINDED INDIVIDUALS THROUGH OUR DEAL SOURCING AND INCUBATION PLATFORM.
CEBINA was founded with the aim of creating, nurturing, and promoting early-stage life sciences companies, to develop new medicines and cutting-edge technologies.
-
Located in a major European biotech hub-Vienna: growing biotech & Pharma community at the heart of Europe
– ~600 life science companies
– 7 Universities, 11 non-university research centres
-
Outstanding business location with a unique quality of life to attract top talent
-
Internationally renowned research institutions and universities: source of new companies and projects for CEBINA
– Vienna‘s IST ranked 3rd among the world‘s best research institutes in 2019
– Key global scientific discoveries include CRISPR/Cas9 – 2020 Nobel prize to Emmanuelle Charpentier
-
Close proximity to key Central and Eastern European institutes
OVERVIEW OF VIENNA'S LIFE SCIENCE ECOSYSTEM
Our Culture
Trust is at the heart of our business and allows for true and long-term partnerships to be fostered with our partners and clients through constant open and transparent communication.
TRUST
Solely focused on the healthcare sector, Intercontinental Capital prides itself on the ability to make a positive impact on society; provide innovative healthcare companies with the resources required to grow, develop better products and deliver better patient outcomes across the globe.
FOCUS
High efficiency is the key value proposition across all advisory elements, from the first meeting to the final delivery.
EFFICIENCY
Led by an entrepreneurial team with vast experience in start-ups, VC funds and financial services, Intercontinental Capital has a unique understanding of entrepreneurs’ requirements and individual needs as their businesses develop over time. With a wealth of cross-industry experience and outside the box thinking, we are able to provide innovative solutions to a wide range of problems whilst having the ‚grit‛ to stick with our clients through thick and thin.
ENTREPRENEURSHIP
The highest ethical standards and moral principles are upheld throughout all operations and activities.
INTEGRITY
Successful Cases
In 2019, we helped Aleva Neurotherapeutics, a Swiss medical device company that develops Deep Brain Stimulation System treatment of Parkinson’s and Essential Tremor, successfully raise $10 million and continue to assist the company to identify a good JV Partner in China.
ALEVA NEUROTHERAPEUTICS
In 2021, we assisted Eirion, a US dermatology company to successfully close $ 40 million Series A Investment and Licensing Deal with Shanghai Haohai Biological Technology Ltd. The companies have signed two product licenses, one license is for Eirion's neuromodulator-based product candidates, ET-01 (topical) and AI-09 (injectable) for aesthetic indications; and a second license is for Eirion's small molecule product candidates, ET-02 (topical) and ET- 03 (oral), which are intended for the treatment of hair loss and hair greying.
EIRION
In 2022, we assisted Nanoflex Robotics, a spin- off from the Multi-Scale Robotics Lab at ETH Zurich successfully raise part of its $10 million series A round of financing.
NANOFLEX ROBOTICS
Patrick Markus Aisher
Chairman & Founding Partner
Patrick is an Anglo-Austrian serial entrepreneur who has been active in early stage businesses since 1990. Throughout his career, he has created and invested in over fifty businesses, exiting twenty via IPO (and twelve via trade sale/licensing deals). Patrick is Chairman of Kinled Holding, a Hong Kong-based private investment company established in 1924, with offices in London, Shanghai, Vienna, Gibraltar, and Zurich. Kinled holds a portfolio of more than 125 companies in the life sciences, digital and financial technology industries.
Patrick is a Founder/Partner in three independently-managed life science funds in Gibraltar, Vienna, and Zurich with $250M AuM, two independently-managed technology funds in London and Vienna with $200M AuM, and is a member of the Swiss Corporate Finance and Private Equity Association.
A strong advocate of seed funding academic research into innovative business concepts, Patrick has financed two independent incubator/accelerators in Austria and Switzerland that work closely with national universities.
Rocky (Li) Shen
Venture Partner
Mr. Shen is currently a Partner of Zhejiang United Investment Group (“ZUIG”), focused on making private equity investments in healthcare and enterprise software sectors. His investment track record includes, Expace, CMR Surgical, Cloudwise, Robocath, Unity Software (NYSE:U), I-Mab Hangzhou, Drug Farm, Xforceplus, FlashDx, Shenqi Medical, Xtalpi, Huadao Bio, StermiRNA, ZSM Pharmaceutical, TYK Medicine, Yoyi Digital, and LavaMed.
Prior to joining ZUIG, Mr. Shen served as an Associate Director in the investment banking division of Guotai Junan Securities, one of largest domestic investment banks in China, where he was responsible for covering and executing M&A and follow-on financing transactions for A-share clients.
Mr. Shen earned an M.B.A. from Samuel Curtis Johnson Graduate School of Management in Cornell University and Bachelor of Economics in Finance from Shanghai University.
Michelle (Dan) Wu
Venture Partner
Ms. Wu is currently Co-founder and CEO at NyquistAI. NyquistAI is building the world's largest Al-empowered data platform for innovators to unlock hidden insights from unstructured data. Entrepreneur with over a decade's hands-on experience to connect real-life business needs with the right technical solutions. Deep understanding of life science business leaders' challenges and passion to solve problems with innovative approaches.
Ms. Wu is also the Founder of Anora and Co-Founder of Waveall. She used to serve as Strategic Planning & BDL Manager at Novartis and Analyst at The Boston Consulting Group. She is also a world traveler and a polyglot.
Ms. Wu holds an M.B.A in Healthcare and Investment from Stanford University Graduate School of Business and a Bachelor’s degree in Foreign Languages and Literatures from Peking University.
Our Venture Partners
Our Venture Partners
Meet the Team
Sara Zhou
CEO & Founding Partner
Prior to founding Intercontinental Capital, Sara served as the Investment Director Of Shanghai Creation Investment(SCI), where she helped build SCI’s overseas investment department from ground zero and raise 4 investment funds. She led due diligence on 8 investments into healthcare Start-ups in US and Israel, such as Surgical Theater, Cleveland Heartlab, and Giview. She also assisted US and Israeli healthcare start-ups to raise funds in China and identify the best ways to enter the Chinese market. Sara successfully helped Zuga medical, a dental implant system producer located in Cleveland, Ohio raise its both series A and series B rounds of financing in China in 2014 and 2015. She also helped MinFound, a CT Developer originally based in Ohio secure $15 Million investment from a state-owned fund in China in 2016.
Sara has gained vast experience of cross-border deals in healthcare sector and has a deep understanding of the difference and gaps between the Chinese healthcare market and overseas healthcare markets. Prior to joining SCI, Sara used to work for Naok Financial and CCG investor relations in New York City.
Sara holds an MBA from INSEAD, an MS in Finance from Case Western Reserve University, and a BS in Economics from University of International Business and Economics. Sara passed CFA level 3 exam in 2013.
A few words from our clients
“Intercontinental Capital has been a great financial advisory firm for us. They understand the marketplace. They identified good potential partners for us and then assisted us in closing a pivotal investment and licensing deal in China. Their ability to navigate complex business discussions was key to getting the deal done. We recommend them unequivocally.”
Jon Edelson , MD
CEO & President
Eirion Therapeutics, Inc (USA)
"I found Intercontinental Capital to be a very profesional, and extremely well connected advisory service. They have contacts at senior levels within the VC's and Strategics in the segments I'm working. Not only are they well connected but they have a deep understanding of my industry offering strategic insights into the needs of the Chinese market in particular."
Mr. Matt Curran
CEO
NanoFlex Robotics (Switzerland)
"The value of doing business in China can no longer be ignored, as the world shifts its attention to China’s growing energy, healthcare, and technological needs. Intercontinental Capital has been with us every step of the way in our business development journey in China. From introductions to high profile investors, to coordinating meetings with commercial partners, to finalizing complex international deals, ICC helped us through the daunting reality of a Western company doing business in China. Importantly, ICC patiently narrowed down the field of potential investors and partners, in order to avoid wasting precious time. As just one example, thanks to ICC’s advisory services, we were able to secure investment from a Chinese fund that has extensive experience in our field and with a partner who understood our technology well. Thanks to ICC’s advisory services we were able to close this deal and we continue to benefit from an ongoing relationship with this shareholder. As an entrepreneur and CEO, I would not hesitate to use ICC services again, as we aim to build new companies with a global outlook for which the value of doing business in China is a priority."
André Mercanzini, PhD
Founder
Aleva Neurotherapeutics SA (Switzerland)
597
Biotech Companies
€13.3b
Sales/Year
41k
Employees
18
Academic Organizations
€850m
R&D Investments